RBC Capital Markets has revised its outlook for Galderma following the company's record H1 2026 sales of $3.13 billion and raised full-year guidance. The upgrade reflects strong execution across the injectables portfolio and accelerating demand in key markets.
Business & M&A
RBC Lifts Galderma Outlook Following H1 Beat
Analyst follows suit on revised guidance after record first-half sales.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |